TANDEM DIABETES CARE INC
TNDMNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for TNDM. That does not mean none is planned.
Get an email about TNDM's next catalysts
Track TANDEM DIABETES CARE (TNDM) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
Tandem Diabetes Care, Inc. is an American medical-device company that develops and markets insulin pumps, automated insulin delivery systems and diabetes-management software. Headquartered in San Diego, California, its principal pump platforms are the t:slim X2 and Tandem Mobi, both of which use the company's Control-IQ+ software with compatible continuous glucose monitors (CGMs).
Website| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
verapamil | Phase 3 | Type1 Diabetes | - | - |
Frequently asked questions
What is in TANDEM DIABETES CARE INC's drug pipeline?→
CatalystAlert tracks 1 drug candidate in TANDEM DIABETES CARE INC's (TNDM) pipeline across Phase 3. Its lead program is verapamil (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TANDEM DIABETES CARE INC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for TANDEM DIABETES CARE INC (TNDM) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track TNDM biotech catalysts?→
Add TNDM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TANDEM DIABETES CARE INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.